JERUSALEM-- (BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) today announced that the U.S. Food and Drug Administration (FDA) has approved GRANIX ® (tbo-filgrastim) Injection for ...

We studied 60 consecutive autologous PBSCTs of 54 pre-treated patients with haematological malignancies at the Medical University Graz, Austria from August 2002 to June 2004. During this period, ...

PURPOSE: This multicenter, randomized, double-blind, active-control study was designed to determine whether a single subcutaneous injection of pegfilgrastim (SD/01, sustained-duration filgrastim; 100 ...

JERUSALEM — Teva Pharmaceutical today announced that the Food and Drug Administration has approved Granix (tbo-filgrastim) Injection for self-administration by patients and caregivers. With the ...

The US Food and Drug Administration (FDA) has expanded the indication for tbo-filgrastim (Granix, Teva), now allowing it to be self-administered by patients and their caregivers. Tbo-filgrastim, a ...

New Granix Syringes Approved for Self-Administration Teva Oncology announced the launch of a new single-use pre-filled syringe for self-administration for Granix (tbo-filgrastim). Teva Oncology ...